Gland PharmaNSE:GLAND -0.49%83 OCF Yield % is 2.70 as of Jun. 28, 2026, which is 214% above its 10-year median of 0.86. GuruFocus rates NSE:GLAND with a GF Score™ of 83/100 and a GF Value™ of ₹2,125.65 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,002 Drug Manufacturers companies, Gland Pharma ranks worse than 55.69% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Gland Pharma OCF Yield % Related Terms
Gland Pharma OCF Yield % Historical Data
* Premium members only.
The historical data trend for Gland Pharma's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Gland Pharma's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gland Pharma (NSE:GLAND) has a OCF Yield % of 2.70 as of Jun. 28, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Gland Pharma and its competitors. This is 214% above median its historical median of 0.86. Over the past decade, Gland Pharma's OCF Yield % has ranged from 0.11 to 2.70. According to the industry distribution chart, Gland Pharma ranks #558 out of 1002 companies in the Drug Manufacturers industry, placing it in the top 55.7%.
Is Gland Pharma's OCF Yield % too high?
Gland Pharma's current OCF Yield % of 2.70 is 214% above median its 10-year median of 0.86. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 2.70. The Drug Manufacturers industry median OCF Yield % is 3.61. Gland Pharma's value of 2.70 is 25.2% below this industry median. Based on the distribution chart, Gland Pharma ranks #558 out of 1002 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Gland Pharma has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's OCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #558 out of 1002 companies for OCF Yield %. This places Gland Pharma in the lower half of its industry. The industry median OCF Yield % is 3.61. Gland Pharma's value of 2.70 is 25.2% below this benchmark. Historically, Gland Pharma's own OCF Yield % has ranged from 0.11 to 2.70 over the past decade. While the company's 10-year median is 0.86 vs. the industry median of 3.61, Gland Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.61, based on 1,002 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gland Pharma's current OCF Yield % of 2.70 is 25.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current OCF Yield % is 2.70, which is 214% above median its own 10-year median of 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,125.65, compared to a current price of ₹2,314.80 — trading 8.9% above its estimated fair value. The current OCF Yield % is 2.70, which is 214% above median its 10-year median of 0.86 and 25.2% below the Drug Manufacturers industry median of 3.61. Gland Pharma's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current OCF Yield % is 2.70 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,314.80 is trading 8.9% above its estimated GF Value™ of ₹2,125.65.
GuruFocus considers Gland Pharma to be Fairly Valued.
Key valuation signals for NSE:GLAND:
OCF Yield %: 2.70 (214% above median its 10-year median of 0.86)
GF Value™: ₹2,125.65 vs. price of ₹2,314.80 (8.9% above fair value)
Industry Position: 25.2% below the Drug Manufacturers median (#558 of 1002)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
83GF Score
Get the complete analysis for NSE:GLAND
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
